North America Gene Expression Analysis Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)
North America Gene Expression Analysis Market: by Type (Consumables, Instruments, Software, Services), Application (Drug Discovery, Diagnostics, Research, Personalized Medicine, Agriculture, Others), Distribution Channels (Direct Sales, Distributors, Online, Retail, Others), Technology (PCR, Microarray, NGS, Sanger Sequencing, Others), Organization Size (Small, Medium, Large) and By North America Historical & Forecast Period (2020-2035) Comprehensive Study 2025
Last Updated: 31-07-2025 | Format: PDF | Report ID:20499 | Author: Sophia
North America Gene Expression Analysis Market (2025-2035)
The North America Gene Expression Analysis Market encompasses a comprehensive suite of products and services to analyze gene expression patterns across a variety of applications including drug discovery, diagnostics, personalized medicine, and agriculture. Characterized by significant R&D initiatives, pivotal genomics funding, and a robust presence of leading industry players, the region is witnessing accelerated adoption of high-throughput technologies like NGS and PCR. Expanding clinical and academic research, coupled with supportive regulatory frameworks, are key contributors to market momentum. Between 2020 and 2035, the market size is expected to grow robustly driven by innovation, strategic partnerships, and increasing investment in precision medicine.
Latest Market Dynamics
Key Drivers
Technological advancements in gene expression platforms, notably the widespread use of Next Generation Sequencing (NGS) and quantitative PCR, are significantly boosting adoption. For example, Illumina
's expansion of NGS-based solutions has accelerated transcriptomics research across universities and clinical laboratories in 2025.
Rising demand for personalized medicine is propelling market growth as healthcare providers leverage gene expression analysis for precise therapeutic and diagnostic strategies. Thermo Fisher Scientific, in 2025, launched tailored solutions to assist hospitals in adopting genomics-driven patient care.
Key Trends
Integration of artificial intelligence and advanced bioinformatics tools is enabling faster and more precise interpretation of complex gene expression datasets. Bio-Rad Laboratories, in 2025, launched new AI-powered analytics solutions for transcriptomics research.
Collaborative ventures between biotechnology firms and clinical research organizations are increasing, leading to the co-development of novel diagnostic assays. In 2025, Agilent Technologies partnered with multiple academic institutions for real-time PCR diagnostics innovation.
Key Opportunities
Expansion of clinical genomics and companion diagnostics offers ample growth potential as regulatory approvals facilitate broader clinical implementation. QIAGEN’s 2025 partnership with North American hospitals provides custom gene panel services.
Growing agricultural genomics initiatives, aimed at enhancing crop yield and resistance, show significant opportunity for gene expression platforms. PerkinElmer’s collaborations in agri-genomics in 2025 set new benchmarks for market expansion.
Key Challenges
High costs associated with advanced gene expression technologies, including sequencing instruments and reagents, remain a challenge for smaller research organizations. Smaller labs in Mexico reported budgeting constraints for adopting Illumina’s high-end sequencers in 2025.
Data management and storage issues due to massive and complex transcriptomics datasets demand scalable infrastructure. In 2025, Bioinformatics companies like Fluidigm and Eurofins Scientific struggled with data harmonization and compliance across multi-site studies.
Key Restraints
Stringent regulatory compliance and data privacy requirements increase market entry barriers, especially for new vendors. F. Hoffmann-La Roche experienced extended approval cycles for new gene diagnostics in Canada in 2025.
Shortage of skilled professionals in advanced genomics data analysis restrains market growth. Despite demand, many clinical research centers in the US highlighted gaps in workforce readiness for NGS-based workflows in 2025.
North America Gene Expression Analysis Market Share by Type, 2025
In 2025, consumables lead the North America Gene Expression Analysis Market by type, representing 37% of total market share, followed by instruments at 28% and software at 15%. Services, kits & reagents, and others account for the remainder. Increased R&D and frequent purchases of consumables such as reagents, assay kits, and microarray slides result in their larger proportion. Instruments maintain strong market demand due to continuous adoption of new gene analysis platforms in both clinical and research settings. Software also commands notable share as advanced analytics and interpretation tools become essential for data-heavy genomics projects.
North America Gene Expression Analysis Market Share by Application, 2025
The largest application segment for gene expression analysis in North America in 2025 is drug discovery, holding a 32% share, trailed by diagnostics at 26%, and research at 18%. Personalized medicine occupies 12%, while agriculture and others constitute the remaining share. Drug discovery stands out due to substantial pharmaceutical investments in genomics for novel therapeutic identification. Diagnostics are rapidly growing driven by increased reliance on molecular tests for disease detection. Research activity continues to expand in academic labs, further contributing to overall market growth.
North America Gene Expression Analysis Market Revenue (2020-2035)
From 2020 to 2035, the North America Gene Expression Analysis Market is projected to grow sharply, starting at $2,800 Million in 2020, surging to $6,500 Million in 2025, and reaching an estimated $15,200 Million by 2035. This growth is underpinned by robust expansion in biopharma, heightened R&D activities, and greater use of genomics in clinical care. Advanced technologies, increasing accessibility, and new product launches from top industry players continue to drive revenue upward through the forecast period.
North America Gene Expression Analysis Market YOY Growth Rate (2020-2035)
Year-over-year growth in the North America Gene Expression Analysis Market remains robust from 2020 to 2035, peaking at 16% during the 2022-2025 period, before moderating to 9% in 2030 and stabilizing at 7.5% by 2035. This pattern reflects accelerated adoption of gene expression technologies in early years and market maturity in the later phases. Ongoing innovation sustains growth though at a moderating pace as technologies mature and saturate key research and clinical segments.
North America Gene Expression Analysis Market, Share by Country, 2025
The United States dominates the regional market in 2025, capturing 76% of total revenue, followed by Canada at 15% and Mexico at 9%. This strong US leadership is driven by extensive investments in biomedical R&D, large-scale genomics projects, and the presence of leading biotechnology firms. Canada and Mexico show steady growth as government funding and private investments in their genomics sectors increase year-over-year.
North America Gene Expression Analysis Market Share by Top Players, 2025
Major players in the North America Gene Expression Analysis Market in 2025 include Thermo Fisher Scientific (21%), Illumina (18%), Agilent Technologies (14%), QIAGEN (11%), and Bio-Rad Laboratories (9%). Other significant contributors are PerkinElmer, Roche, and GE Healthcare. These companies maintain high market shares through broad product portfolios, robust R&D investments, and expansive geographic reach, setting competitive benchmarks across core genomics platforms and services.
North America Gene Expression Analysis Market Share by Buyer Type, 2025
Life sciences research institutions comprise the largest buyer segment at 39%, followed by pharmaceutical and biotech companies at 27%, and clinical laboratories at 18%. Academic entities and contract research organizations make up the remaining share. Robust research funding, together with biopharma’s growing reliance on gene expression for drug development, drives demand from these core segments.
June 2024: Illumina unveiled its new scalable GEX-Nova platform, driving higher throughput and cost-efficacy for large-scale gene expression studies across major North American institutions.
July 2024: Thermo Fisher Scientific expanded its digital PCR product line catering to clinical diagnostic providers, supporting accelerated adoption for personalized medicine workflows.
August 2024: QIAGEN introduced advanced bioinformatics tools in collaboration with hospital networks, aiming to streamline clinical genomics data pipelines in the US and Canada.
September 2024: Agilent Technologies announced partnerships with multiple academic consortia to enhance PCR-based diagnostic assays for rare diseases.
October 2024: Bio-Rad Laboratories launched a modular AI-driven analytics software designed to support multi-center transcriptomics research across leading North American universities.
Frequently Asked Questions
About the Author
Sophia
Lead Industry Analyst
Sophia is a Lead Industry Analyst specializing in market research, industry analysis, and business consulting across Healthcare. Sophia brings a commercially grounded perspective to sectors shaped by changing demand, innovation, and competitive dynamics, helping turn complex market trends into clear strategic insights for business decision-makers. With 10+ years of experience across research, analytics, and strategic advisory roles, Sophia has helped organizations translate data into actionable growth strategies.
